The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $116.85

Today's change+0.35 +0.30%
Updated April 28 4:02 PM EDT. Delayed by at least 15 minutes.
 

Taro Pharmaceutical Industries Ltd

NYSE: TARO
Last

(U.S.) $116.85

Today's change+0.35 +0.30%
Updated April 28 4:02 PM EDT. Delayed by at least 15 minutes.

Taro Pharmaceutical Industries Ltd crosses above 20-day moving average

Taro Pharmaceutical Industries Ltd closed up Friday by (U.S.)$0.35 or 0.30% to (U.S.)$116.85 and crossing above its 20-day moving average. Over the last five days, shares have gained 1.11% and 11.00% year to date. Shares have underperformed the S&P 500 by 30.83% during the last year.

Key company metrics

  • Open(U.S.) $116.41
  • Previous close(U.S.) $116.50
  • High(U.S.) $118.31
  • Low(U.S.) $115.84
  • Bid / Ask-- / --
  • YTD % change+11.00%
  • Volume64,681
  • Average volume (10-day)56,301
  • Average volume (1-month)71,730
  • Average volume (3-month)101,377
  • 52-week range(U.S.) $92.28 to (U.S.) $150.75
  • Beta0.82
  • Trailing P/E9.99×
  • P/E 1 year forward10.62×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) $11.69
Updated April 28 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+51.59%

Based on its net profit margin of 51.59%, Taro Pharmaceutical Industries Ltd is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.51%Sector:HealthcareIndustry:Pharmaceuticals - Diversified

Latest Company News

View more News

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedDec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016
Revenue220229234265
Total other revenue--------
Total revenue220229234265
Gross profit167177183224
Total cost of revenue53515141
Total operating expense91879183
Selling / general / administrative20212223
Research & development18151820
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income129142143182
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax161160140138
Income after tax140124110115
Income tax, total20363023
Net income140124110115
Total adjustments to net income--------
Net income before extra. items140124110115
Minority interest0000
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items140124110115
Inc. avail. to common incl. extra. items140124110115
Diluted net income140124110115
Dilution adjustment--------
Diluted weighted average shares41414243
Diluted EPS excluding extraordinary itemsvalue per share3.423.002.602.68
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share3.423.002.602.69